3rd Annual Pharmacoequity Conference | May 3, 2024
For the third year, CP3 was proud to present the Pharmacoequity Conference, the first and only conference devoted to the topic. This year was our biggest yet with over 400 registrants joining us in person and on Zoom to listen to an incredible slate of research, policy, and payer expert speakers (pictured above), plus keynote Dr. Fumiko Chino’s address “Financial Toxicity in America.” The conference was supported in part by a grant from AHRQ, and we received generous support from sponsors Arnold Ventures and the University of Pittsburgh School of Pharmacy. Funds from the Physician Inclusion Council of UPMC and Pitt (PICUP) helped us fund travel assistance awards to 5 graduate and medical students interested in pharmacoequity (pictured below). The full agenda and conference recording are hosted on our web page.
|
|
|
|
Two CP3 faculty affiliates were honored at the recent Society of General Internal Medicine (SGIM) annual meeting. For his support and guidance of trainees, Dr. Tim Anderson was recognized with the Frederick L. Brancati Mentorship & Leadership Award. Dr. Utibe Essien, former CP3 faculty, was awarded Outstanding Junior Investigator of the Year. Congratulations to both on these well-deserved honors!
Additionally, faculty affiliate Tina Batra Hershey, JD, MPH received the Pitt School of Public Health James L. Craig Excellence in Teaching Award. Read more about the award and her work here.
|
|
|
|
|
|
Visiting Scholar – Dr. Dan Hartung
It’s hard to believe that Dr. Dan Hartung’s time with CP3 is almost up! Dr. Hartung, Professor of Pharmacy in the Oregon State University College of Pharmacy, joined us April 1 as a Visiting Scholar. In his nearly three months on the Pitt campus, he has presented his research at the Pharmacoequity Conference and the Center for Research on Health Care’s Health Services Research seminar and has collaborated with CP3 faculty on projects, including an analysis of uptake and price of new high-cost prescription drugs recently on the market. We’ve also enjoyed introducing Dr. Hartung to all the breweries Pittsburgh has to offer. Though he’ll head back to Portland soon, Dr. Hartung will continue to collaborate with CP3 faculty.
|
|
In March, the HumAn-1 trial reached another major milestone! The first trial participants, enrolled in March 2023 in Dhaka, Bangladesh, have completed all study visits (pictured above). HuMan-1 is a randomized controlled trial comparing insulin glargine, a long-acting analogue insulin, against human insulin among children and young adults living with T1D in lower resource settings. In addition, at the International Alliance for Diabetes Action (IADA) 4th Symposium on Diabetes in Humanitarian Crises, Pitt PI Dr. Jing Luo moderated the session “Making Affordable Insulin Access a Global Reality.”
|
|
Drug Shortages
Congratulations to CP3 Associate Director Dr. Katie Suda, who won Pitt's 2024 Big Proposal Bootcamp! Dr. Suda has been awarded a $20,000 prize to advance her research on drug shortages into a large-scale project.
|
|
|
|
Risk Prediction
For many years, Drs. Walid Gellad and Jenny Lo-Ciganic have worked together on a suite of overdose risk prediction projects. In April, the two CP3 faculty had their own session in which to present their work to attendees of the Rx and Illicit Drug Summit, billed as the largest event that addresses the overdose crisis. Their talk highlighted their expertise and careful approach to developing and implementing risk prediction models. You can read more about this work here; please contact us to learn more or to discuss collaboration.
|
|
|
|
|
|
Selected Recently Published Papers
The Management of Elevated Blood Pressure in the Acute Care Setting: A Scientific Statement From the American Heart Association
Adam P. Bress, Timothy S. Anderson, John M. Flack, Lama Ghazi, Michael E. Hall, Cheryl L. Laffer, Carolyn H. Still, Sandra J. Taler, Kori S. Zachrison, Tara I. Chang and on behalf of the American Heart Association Council on Hypertension; Council on Cardiovascular and Stroke Nursing; and Council on Clinical Cardiology
Hypertension, June 3, 2024
Industry Payments to Physicians Endorsing Drugs and Devices on a Social Media Platform
Sonia Persaud, MPH; Samer Al Hadidi, MD, MS; Timothy S. Anderson, MD, MAS; Grace Gallagher, MPH; Susan Chimonas, PhD; Deborah Korenstein, MD; Aaron P. Mitchell, MD, MPH
JAMA, May 30, 2024
COVID-19 pandemic and trends in clinical outcomes and medication use for patients with established atrial fibrillation: A nationwide analysis of claims data
Inmaculada Hernandez, Lanting Yang, Shangbin Tang, Teresa Cameron, Jingchuan Guo, Nico Gabriel, Utibe R. Essien, Jared W. Magnani, Walid F. Gellad
American Heart Journal Plus: Cardiology Research and Practice, June 2024
Barriers to Buprenorphine Dispensing by Medicaid-Participating Community Retail Pharmacies
Patricia R. Freeman, RPh, PhD; Lindsey R. Hammerslag, PhD; Katherine A. Ahrens, PhD; Michael Sharbaugh, MPH; Adam J. Gordon, MD; Anna E. Austin, PhD; Julie M. Donohue, PhD; Lindsay D. Allen, PhD; Andrew J. Barnes, PhD; Jeffery C. Talbert, PhD
JAMA Health Forum, May 17, 2024
Active surveillance pharmacovigilance for Clostridioides difficile infection and gastrointestinal bleeding: an analytic framework based on case-control studies
Ravy K Vajravelu, Amy R Byerly, Robert Feldman, Scott D Rothenberger, Robert E Schoen, Walid F Gellad, James D Lewis
eBioMedicine, April 22, 2024
An Explainable Machine Learning Framework for Predicting the Risk of Buprenorphine Treatment Discontinuation for Opioid Use Disorder among Commercially Insured Individuals
Jabed Al Faysal, Md. Noor-E-Alam, Gary J. Young, Wei-Hsuan Lo-Ciganic, Amie J. Goodin, James L. Huang, Debbie L. Wilson, Tae Woo Park, Md Mahmudul Hasan
Computers in Biology and Medicine, April 22, 2024
Intravascular Microaxial Left Ventricular Assist Device Manufacturer Payments to Cardiologists and Use of Devices
Sanket S Dhruva, Joseph S Ross, Michael A Steinman, Siqi Gan, Sruthi Muluk, Timothy S Anderson
JAMA, April 10, 2024
Drug Shortages Prior to and During the COVID-19 Pandemic
Katherine Callaway Kim, MPH; Scott D. Rothenberger, PhD; Mina Tadrous, PharmD, PhD; Inmaculada Hernandez, PharmD, PhD; Walid F. Gellad, MD, MPH; Joshua W. Devine, PharmD, PhD; Tina B. Hershey, JD, MPH; Lisa M. Maillart, PhD; Katie J. Suda, PharmD, MS
JAMA Network Open, April 5, 2024
|
|
|
|
Medication adherence is a notorious issue for long-term medications. Is it different for weight-loss medications, like Ozempic and Wegovy? The New York Times interviewed experts, including CP3's Dr. Walid Gellad, to learn more.
CP3 Faculty Affiliate Dr. Bryant Shuey spoke with CNN Health and the New York Times about his recent JAMA Health Forum paper describing rising rates of women obtaining care for alcohol misuse during the pandemic. “Drinking has increased in the last decade among women, particularly during the pandemic, in comparison to men,” Shuey said. “That uptick
in drinking is likely contributing to the really serious alcohol-related liver disease, mood disorders, alcohol withdrawal problems and heart and gastric concerns we found in our study.”
|
|
|
|
CP3 faculty affiliate Dr. Lucas Berenbrok is one of the organizers of the Inaugural OTC Hearing Aid and Hearing Self-Care Symposium, taking place on campus June 7. This event is dedicated to bringing together thought leaders from pharmacy, audiology, and public health to discuss how the newest class of hearing aids (over-the-counter) can increase patient access to hearing healthcare in the United States. Pharmacist and audiologist continuing education (CE) are available. Get more information and register here.
|
|
|
 |
|
